Arcutis Biotherapeutics, Inc. Profile Avatar - Palmy Investing

Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials …

Biotechnology
US, Westlake Village [HQ]

Risk Factors

By Management
10-K
  1. If ZORYVE or any of our product candidates that are approved for marketing are found to have been improperly promoted for off-label uses by us, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, product liability claims and significant fines, penalties and sanctions, and our brand and reputation could be harmed.

  2. Even if we receive regulatory approval of our product candidates, we will be subject to extensive and ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.

  3. The terms of our loan and security agreement require us to meet certain operating and financial covenants, including a minimum financing covenant, and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.

Get PRO Today.

Read 22 more risk factors of Arcutis Biotherapeutics, Inc.

End of ARQT's Analysis
CIK: 1787306 CUSIP: 03969K108 ISIN: US03969K1088 LEI: - UEI: -
Secondary Listings
ARQT has no secondary listings inside our databases.